Skip to main navigation

About Us
Programs
Join Us
Investors
Contact Us

Press Releases

Investors & Media

Overview
Press Releases
Events & Presentations
Financials
Stock Information
Analyst Coverage
Governance
Contact & FAQs

Stockholder Tools

Print Page
RSS Feeds
Email Alerts
Contact Us

Year

May 16, 2022

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

May 16, 2022

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

March 30, 2022

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

March 2, 2022

Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference

December 15, 2021

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

November 15, 2021

Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

September 17, 2021

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

August 16, 2021

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

July 19, 2021

Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors

July 2, 2021

Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investors & Media

Overview
Press Releases
Events & Presentations
Financials
Stock Information
Analyst Coverage
Governance
Contact & FAQs

Stockholder Tools

Print Page
RSS Feeds
Email Alerts
Contact Us

About Us
Programs
Join Us
Investors
Contact Us

© 2022 Aerovate Therapeutics, Inc. All Rights Reserved. | Privacy Policy | Terms of Use